Therefore, targeting RSK could be an efficient approach for eliminating tumor-initiating cells via YB-1 inactivation in triple-negative breast cancer (TNBC) [15] lacking the expression of estrogen, progesterone, and HER2 receptors. Here, YBX1 is linked to neoplasm.